GREY:ATBPF - Post by User
Post by
funky99on Jul 29, 2015 6:32pm
118 Views
Post# 23973777
Bloom Burton Monday Biotech Deal Review - ATE Coverage
Bloom Burton Monday Biotech Deal Review - ATE CoverageAntibe Therapeutics ATE.V getting some press by Bloom Burton this week!
https://www.bloomburton.com/monday-deal-review-july-27-2015/
Antibe Therapeutics Inc. (TSX-V:ATE), announced the addition to its product pipeline of ATB-340, a hydrogen sulfide-releasing derivative of aspirin. In pre-clinical studies, ATB-340 has been shown to be at least as potent as aspirin in blocking the COX enzyme and reducing blood clotting. However, while aspirin produced significant stomach and intestinal ulceration and bleeding in rats, ATB-340 did not. In human blood, ATB-340 inhibited platelet aggregation as effectively as aspirin.